Zealand Pharma's earnings call was predominantly positive, highlighting strong partnerships, a robust financial position, and promising advancements in their obesity management programs. While there are some challenges, such as manufacturing delays and exchange rate losses, these are outweighed by the strategic developments and financial strength of the company.

Company Guidance -

Q3 2025

During the Zealand Pharma Interim Report Half Year 2025 Conference Call, the company provided detailed guidance on its key obesity programs, petrelintide and survodutide. Zealand Pharma expects Phase II data for petrelintide by the end of 2025 and plans to initiate a Phase III program in the second half of 2026. The petrelintide program, partnered with Roche, will also see the initiation of Phase II trials for a combination product in the first half of 2026. The company highlighted its robust financial position, with a cash position of DKK 16.6 billion as of June 30, 2025, largely due to a DKK 9.2 billion upfront payment from Roche. For the fiscal year, Zealand Pharma confirmed its financial guidance on net operating expenses between DKK 2 billion and DKK 2.5 billion. The management emphasized ongoing efforts to address the obesity market's needs with differentiated therapies, aiming for weight loss in the range of 10% to 20% with improved tolerability.

Strong Partnership with Roche

Zealand Pharma's collaboration with Roche for the petrelintide program is advancing well, with significant manufacturing investments in a high-volume, high-throughput facility in the U.S. and a robust clinical development plan.

Robust Financial Position

The company reported revenue of DKK 9.1 billion for the first half of 2025, largely due to the initial upfront payment from Roche. Cash position increased to DKK 16.6 billion, supporting future investments and obligations.

Advancement in Weight Management Programs

Zealand Pharma has significant momentum in the development of its obesity management pipeline with promising Phase II data expected for petrelintide and Phase III data for survodutide.

Strategic Leadership Appointments

The company strengthened its leadership team with key appointments, including a new Chief Scientific Officer and Chief Development Officer, to drive innovation and regulatory strategies.

Potential in MASH Treatment

Survodutide shows promising results in improving liver fibrosis in MASH patients, with Boehringer Ingelheim's robust Phase III program underway.

Zealand Pharma (ZLDPF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZLDPF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-1.27 / -	-0.585	―	―	―
Aug 14, 2025	2025 (Q2)	17.05 / 16.47	-0.717	2396.37% (+17.19)
May 08, 2025	2025 (Q1)	-0.34 / -0.74	-0.579	-28.03% (-0.16)
Feb 20, 2025	2024 (Q4)	-0.80 / -0.64	-0.696	8.17% (+0.06)
Nov 07, 2024	2024 (Q3)	-0.56 / -0.58	0.198	-395.28% (-0.78)
Aug 15, 2024	2024 (Q2)	-0.62 / -0.72	-0.858	16.38% (+0.14)
May 16, 2024	2024 (Q1)	-0.61 / -0.58	-0.596	2.88% (+0.02)
Feb 27, 2024	2023 (Q4)	-0.60 / -0.70	-0.81	13.97% (+0.11)
Nov 09, 2023	2023 (Q3)	-0.36 / 0.20	-0.661	129.95% (+0.86)
Aug 17, 2023	2023 (Q2)	-0.73 / -0.86	-1.722	50.18% (+0.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZLDPF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$53.68	$55.02	+2.50%
May 08, 2025	$68.22	$63.26	-7.27%
Feb 20, 2025	$108.08	$106.34	-1.61%
Nov 07, 2024	$125.31	$119.04	-5.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zealand Pharma (ZLDPF) report earnings?

Zealand Pharma (ZLDPF) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Zealand Pharma (ZLDPF) earnings time?

Zealand Pharma (ZLDPF) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZLDPF EPS forecast?

ZLDPF EPS forecast for the fiscal quarter 2025 (Q3) is -1.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing